Anti-VEGF in diabetic retinopathy and diabetic macular edema

被引：1

作者：

Habbu, Karishma ^{[1
]}

Singh, Rishi P. ^{[1
]}

机构：

[1] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA

来源：

EXPERT REVIEW OF OPHTHALMOLOGY | 2016年 / 11卷 / 06期

关键词：

Diabetes; diabetic retinopathy; diabetic macular edema; retina; injection; anti-VEGF;

D O I：

10.1080/17469899.2016.1251312

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Introduction: Anti-VEGF intravitreal injections have revolutionized the treatment of diabetic retinopathy and diabetic macular edema in particular. This review focuses on agents used in anti-VEGF treatment and documents evidence for their efficacy over laser photocoagulation in the treatment of diabetic macular edema. Areas covered: This study documents data from major clinical trials evaluating the safety and efficacy of the following anti-VEGF drugs: ranibizumab (Lucentis), bevacizumab (Avastin) and aflibercept (Eylea). We also discuss the ocular and systemic side effects of intravitreal anti-VEGF therapy as well as the future direction of anti VEGF therapy. Expert commentary: We describe some of the unknowns regarding anti-VEGF therapy including the lack of data on long term outcomes, the cost/benefit analysis over pan retinal laser treatment, and the heavy demand on patients for consistent follow up.

引用

页码：443 / 451

页数：9

共 70 条

[1] Perspectives on diabetic retinopathy [J].

Aiello, LM .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (01) :122-135

[2] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[3] Towards a rational approach to combination therapy for neovascular age-related macular degeneration [J].

Arroyo, Jorge G. .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (02) :130-131

[4] A multimodal approach to diabetic macular edema [J].

Au, Adrian ;

Singh, Rishi P. .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (03) :545-553

[5] Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema A Systematic Review and Meta-analysis [J].

Avery, Robert L. ;

Gordon, Gabriel M. .

JAMA OPHTHALMOLOGY, 2016, 134 (01) :21-29

[6]

Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399

[7] Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab [J].

Bakri, S. J. ;

Pulido, J. S. ;

McCannel, C. A. ;

Hodge, D. O. ;

Diehl, N. ;

Hillemeier, J. .

EYE, 2009, 23 (01) :181-185

[8] Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies [J].

Brown, David M. ;

Schmidt-Erfurth, Ursula ;

Do, Diana V. ;

Holz, Frank G. ;

Boyer, David S. ;

Midena, Edoardo ;

Heier, Jeffrey S. ;

Terasaki, Hiroko ;

Kaiser, Peter K. ;

Marcus, Dennis M. ;

Nguyen, Quan D. ;

Jaffe, Glenn J. ;

Slakter, Jason S. ;

Simader, Christian ;

Soo, Yuhwen ;

Schmelter, Thomas ;

Yancopoulos, George D. ;

Stahl, Neil ;

Vitti, Robert ;

Berliner, Alyson J. ;

Zeitz, Oliver ;

Metzig, Carola ;

Korobelnik, Jean-Francois .

OPHTHALMOLOGY, 2015, 122 (10) :2044-2052

[9] Biochemistry and molecular cell biology of diabetic complications [J].

Brownlee, M .

NATURE, 2001, 414 (6865) :813-820

[10] The pathobiology of diabetic complications - A unifying mechanism [J].

Brownlee, M .

DIABETES, 2005, 54 (06) :1615-1625

← 1 2 3 4 5 6 7 →